ANXA1 and Stroke: These data provide further evidence that not only is AnxA1 able to reduce the prothrombotic potential of platelets, but it is also able to reduce the velocity at which platelets form platelet–platelet aggregates, thereby reducing the risk of thrombosis, eg, subsequent thrombotic events in stroke.